EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neutralizing antibody against GDF15 for treatment of cancer-associated cachexia

Junyi Xiong iD, Guojin Wu, Jinying Ning, Junlin Yan, Jian Yang, Jinsen Kang

PLOS ONE · 22.08.2024 · 19 (8) · e0309394

DOI: 10.1371/journal.pone.0309394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 22.08.2024. Verfasst von Junyi Xiong und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, China. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Cachexia, Antibodies, Neutralizing, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Xinjiang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GDF15 (growth differentiation factor 15), also known as macrophage inhibitory cytokine 1 (MIC-1), is a circulating protein involved in the regulation of energy balance and weight control. Elevated levels of GDF15 have been associated with cachexia and reduced survival rates in cancer patients. Through the activation of the GFRAL (GDNF-family receptor α-like)-RET (Rearranged during Transfection) signaling pathway, GDF15 can induce weight loss, making it a potential target for treating cachexia. Currently, there are no approved antibody drugs specifically targeting GDF15 for cancer cachexia treatment. However, efforts have been made to develop antibody-based therapeutics against this emerging target. In this study, we generated a monoclonal antibody KY-NAb-GDF15 against GDF15 that effectively blocks downstream signaling mediated by GFRAL upon stimulation by GDF15. This antibody demonstrates robust neutralizing activity and exhibits high binding specificity. Importantly, our findings indicate that this antibody holds promise in alleviating cancer-induced cachexia and mitigating chemotherapy-induced weight loss, thereby offering significant therapeutic potential for managing cancer cachexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15CachexiaAntibodies, NeutralizingNeoplasmsHumansAnimalsMiceCell Line, TumorSignal TransductionAntibodies, MonoclonalGlial Cell Line-Derived Neurotrophic Factor Receptors

Substanzen

Growth Differentiation Factor 15Antibodies, NeutralizingGDF15 protein, humanAntibodies, MonoclonalGlial Cell Line-Derived Neurotrophic Factor Receptors

Autor:innen und Institutionen

  • College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, China.
  • KYINNO Biotechnology (Beijing) Co., Ltd., Beijing, China.
  • Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, Urumqi, Xinjiang, China.

ORCID-Profile: Junyi Xiong

Förderung

  • Key Research and Development Program of Xinjiang

Zitieren

APA

Xiong, J., Wu, G., Ning, J., Yan, J., Yang, J., & Kang, J. (2024). Neutralizing antibody against GDF15 for treatment of cancer-associated cachexia. PLOS ONE, 19(8), e0309394. https://doi.org/10.1371/journal.pone.0309394

Vancouver

Xiong J, Wu G, Ning J, Yan J, Yang J, Kang J. Neutralizing antibody against GDF15 for treatment of cancer-associated cachexia. PLOS ONE. 2024;19(8):e0309394. doi:10.1371/journal.pone.0309394

BibTeX
@article{Xiong2024,
  author = {Xiong, Junyi and Wu, Guojin and Ning, Jinying and Yan, Junlin and Yang, Jian and Kang, Jinsen},
  title = {Neutralizing antibody against GDF15 for treatment of cancer-associated cachexia},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {8},
  pages = {e0309394},
  doi = {10.1371/journal.pone.0309394}
}
Kostenlos starten →